Hepatitis: Omata M

Anonymous00371, McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jafri W, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R. · Centenary Research Institute, AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, University of Sydney, NSW 2006, Australia. · J Gastroenterol Hepatol. · Pubmed #17444847 No free full text.

This publication has no abstract.

Omata M. · No affiliation provided · Intern Med. · Pubmed #15575231 links to  free full text

This publication has no abstract.

Shiratori Y, Yoshida H, Omata M. · No affiliation provided · Jpn J Clin Oncol. · Pubmed #10857497 links to  free full text

This publication has no abstract.

Omata M. · No affiliation provided · Nippon Naika Gakkai Zasshi. · Pubmed #10341638 No free full text.

This publication has no abstract.

Masuzaki R, Yoshida H, Tateishi R, Shiina S, Omata M. · Department of Gastroenterology, University of Tokyo, Bunkyo-ku, Tokyo, Japan. · Best Pract Res Clin Gastroenterol. · Pubmed #19187872 No free full text.

Abstract: Hepatocellular carcinoma (HCC) is a common malignancy worldwide, and its incidence is increasing in the United States and elsewhere. The prognosis of HCC patients depends not only on tumour stage but also on the background liver function reservoir. Current options for the treatment of HCC are surgical resection, liver transplantation, transcatheter arterial embolization, chemotherapy, and percutaneous ablation therapy. The choice of optimal treatment for individual patients, especially those at an earlier cancer stage, is sometimes controversial. Short-term prognosis of HCC patients has been much improved recently due to advances in early diagnosis and treatment, although long-term prognosis is as yet far from satisfactory as indicated by the overall survival at 10 years after apparently curative treatment of only 22-35%. Prevention of HCC recurrence, or tertiary prevention, is one of the most challenging tasks in current hepatology.

Omata M, Yoshida H, Shiratori Y. · Department of Gastroenterology, University of Tokyo Graduate School of Medicine, Tokyo, Japan. · Clin Gastroenterol Hepatol. · Pubmed #16234063 No free full text.

Abstract: Chronic hepatitis C is a leading cause of hepatocellular carcinoma (HCC) worldwide. Prevention of chronic hepatitis C-related HCC is one of the most important issues in current hepatology. We conducted 2 cohort studies, one among patients with chronic hepatitis C mostly without cirrhosis and another among those with compensated cirrhosis, to confirm the prevention of HCC by interferon. We also conducted a randomized controlled study among patients with HCV-related HCC treated completely by ablation to examine the effect of interferon therapy on prognosis. With the chronic hepatitis C cohort, we showed that the risk of HCC development, which was strongly associated with the stage of liver fibrosis, age, and gender, was reduced by interferon therapy to one fifth among sustained virologic responders compared with untreated patients. Life expectancy was also significantly prolonged. The benefit of interferon therapy was greater among those with the higher risk of HCC. We confirmed efficacy in HCC-prevention in the second study among patients with compensated cirrhosis who received interferon therapy. The third study among HCC patients who had received complete tumor ablation showed that interferon therapy was associated with better survival, primarily as a result of the preservation of liver function and also probably prevention of recurrence. We have shown beneficial effects of interferon therapy on HCC prevention and liver function preservation. They were the strongest in sustained virologic responders. Further improvement in prognosis may be expected in the future because the current combination therapy of pegylated interferon and ribavirin shows higher efficiency than interferon alone.

Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH, Omata M, Anonymous00046. · Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan. · Liver Int. · Pubmed #15910483 No free full text.

Abstract: BACKGROUND/AIMS: A large amount of new data on the treatment of chronic hepatitis B has become available such that the 2003 consensus statement requires revision and update. METHODS: New data were presented, discussed and debated in an expert pre-meeting to draft a revision. The revised contents were finalized after discussion in a general meeting of APASL. RESULTS: Conceptual background, including the efficacy and safety profile of currently available and emerging drugs, was reviewed. Nineteen recommendations were formed and unresolved issues and areas for further study were suggested. CONCLUSION: The current therapy of chronic hepatitis B is modestly effective but not satisfactory. The development of new drugs and new strategies is required to further improve the outcomes of treatment.

Kanai F, Omata M. · Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo. · Nippon Rinsho. · Pubmed #15779394 No free full text.

This publication has no abstract.

Goto T, Kato N, Omata M. · Department of Gastroenterology, JR Tokyo General Hospital. · Nippon Rinsho. · Pubmed #15453352 No free full text.

This publication has no abstract.

Kato N, Omata M. · Department of Gastroenterology, Graduate School of Medicine, University of Tokyo. · Nippon Rinsho. · Pubmed #15453342 No free full text.

This publication has no abstract.

Gunji T, Omata M. · Department of Gastroenterology, The University of Tokyo Hospital. · Nippon Rinsho. · Pubmed #15453336 No free full text.

This publication has no abstract.

Otsuka M, Tanaka Y, Kato N, Omata M. · Department of Gastroenterology, Graduate School of Medicine, University of Tokyo. · Nippon Rinsho. · Pubmed #15453298 No free full text.

This publication has no abstract.

Goto T, Kato N, Omata M. · Department of Gastroenterology, JR Tokyo General Hospital. · Nippon Rinsho. · Pubmed #15453283 No free full text.

This publication has no abstract.

Hoshida Y, Kato N, Omata M. · Department of Gastroenterology, Graduate School of Medicine, University of Tokyo. · Nippon Rinsho. · Pubmed #15359867 No free full text.

This publication has no abstract.

Tateishi R, Yoshida H, Omata M. · Department of Gastroenterology, University of Tokyo. · Nippon Rinsho. · Pubmed #15359865 No free full text.

This publication has no abstract.

Kondo Y, Tateishi R, Yoshida H, Omata M. · Department of Gastroenterology, University of Tokyo. · Nippon Rinsho. · Pubmed #15359853 No free full text.

This publication has no abstract.

Yoshida H, Omata M. · Department of Gastroenterology, University of Tokyo Graduate School of Medicine. · Nippon Rinsho. · Pubmed #15359842 No free full text.

This publication has no abstract.

Otsuka M, Kato N, Omata M. · Department of Gastroenterology, Graduate School of Medicine, University of Tokyo. · Nippon Rinsho. · Pubmed #15359790 No free full text.

This publication has no abstract.

Kato J, Shiratori Y, Kato N, Omata M. · Department of Medicine and Medical Science, Okayama University Graduate School of Medicine and Dentistry. · Nippon Rinsho. · Pubmed #15359769 No free full text.

This publication has no abstract.

Kato N, Omata M. · Department of Gastroenterology, Graduate School of Medicine, University of Tokyo. · Nippon Rinsho. · Pubmed #15359764 No free full text.

This publication has no abstract.

Tanaka M, Yokosuka O, Omata M. · Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University. · Nippon Rinsho. · Pubmed #15359761 No free full text.

This publication has no abstract.

Omata M. · Department of Gastroenterology, Graduate School of Medicine, University of Tokyo. · Nippon Rinsho. · Pubmed #15359754 No free full text.

This publication has no abstract.

Omata M, Yoshida H. · Department of Gastroenterology, University of Tokyo, Japan. · Liver Transpl. · Pubmed #14762850 links to  free full text

Abstract: Viral hepatitis, by either hepatitis C virus (HCV) or hepatitis B virus (HBV), is the dominant cause of hepatocellular carcinoma (HCC). This is to say that HCC may be prevented by controlling viral infection. Horizontal transmission of HCV has become obsolete owing to the discovery of the virus. Vertical transmission of HBV during delivery has been effectively prevented by vaccination and immunization of neonates. The efficacy of interferon therapy against HCV was recently much improved. We now possess several powerful antiviral drugs against HBV. There has been progress also in the treatment of HCC, and together with advances in diagnostics facilitating HCC detection at an early stage, tumor nodules can often be completely removed either by medical ablation or surgical resection. Nevertheless, recurrence of HCC after apparently curative treatment is extraordinarily frequent, since the remaining liver is still at a particularly high risk of HCC. An effective treatment of HCC should include measures to control de novo carcinogenesis.

Omata M, Yoshida H. · Dept. of Gastroenterology, University of Tokyo, Tokyo, Japan. · Scand J Gastroenterol Suppl. · Pubmed #12797682 No free full text.

Abstract: Hepatocellular carcinoma (HCC) is one of the most important medical problems facing the Asian-Pacific region, where the prevalence of chronic hepatitis B and C is so high. Every year, we have approximately 500 admissions to our department due to this malignancy. It is of utmost importance that we have efficient screening, diagnosis and treatment. Over the past several years, there has been steady improvement in elucidating the super-high risk group for HCC, and in the management of these patients. I discuss how effectively we can screen patients by using three tests, conventional AFP, AFP-L3 (lectin fraction) and DCP (des-gamma-carboxy-prothrombin). With these tests we can detect HCC as small as 10 mm. In addition, imaging technology including CT-angiography can effectively pick up small cancer nodules. However, they are not always readily available in all Asian countries. Thus, diagnostic procedures and treatment methods can be modified in each country depending on the situation. One such treatment modality is the percutaneous therapy. The recent introduction of radiofrequency ablation (RFA) has dramatically changed our daily clinical practice. The time needed to treat cancer nodules of 2 to 3 cm in size has been reduced from 1 month or longer with ethanol injection to less than a week with RFA. However, the most important issue is to prevent infection and progression from chronic hepatitis to HCC. The recent introduction of improved antiviral therapy makes us feel optimistically that we might eventually have a comprehensive strategy for HCC in the region where it is most needed.

Otsuka M, Kato N, Yoshida H, Yoshida H, Shiratori Y, Omata M. · Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. · Uirusu. · Pubmed #12685322 No free full text.

This publication has no abstract.